about
Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells.Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophySerum Creatinine Distinguishes Duchenne Muscular Dystrophy from Becker Muscular Dystrophy in Patients Aged ≤3 Years: A Retrospective Study.MLPA identification of dystrophin mutations and in silico evaluation of the predicted protein in dystrophinopathy cases from India.Dystrophin isoform induction in vivo by antisense-mediated alternative splicing.A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new groundThe status of exon skipping as a therapeutic approach to duchenne muscular dystrophyAntisense therapy in neurologyAntisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy.Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice.Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy.Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophyAssessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the eDystrophin online databaseEteplirsen in the treatment of Duchenne muscular dystrophyEfficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs.Skipping Multiple Exons to Treat DMD-Promises and Challenges.Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts.
P2860
Q27308743-D680ACA7-347C-4A57-AFE0-0D7DB10F3F7BQ28069201-7C9A8234-08BF-485E-B15E-41BCA57BAA70Q33646732-75B34F96-2419-4FC2-B8F7-A034FF2819F7Q33796134-4D561123-7DEB-4A80-8C37-ED13C4148D87Q33930110-7A1F41BA-83C4-43EC-AC00-620E7C2F6597Q33950888-60E85FF3-BE48-4174-9814-D1FFE54D09A7Q34473336-58EF8098-579F-41D4-BD0D-A2C9DF37EE62Q34608717-8DB08511-ABB8-4985-8EFC-5168DE5D7FE4Q35817700-96786E15-80F8-4BE5-8765-8859603A6806Q36187202-8F403757-19F0-4EF1-8C1B-B06BD198AC22Q36297940-E428E8E1-3C53-4293-8BE3-9964F7302F56Q36598414-65EE4E99-26C6-4121-9D5D-DC4CF3C4A907Q37042659-DF0B7EF8-1D04-4E81-AACB-1BBB2919767DQ37053612-6AE4B387-EFF9-48A4-BCC2-3D8C997C33B2Q37105210-3C37307D-4B4A-4581-9937-9ED02F91E54AQ37109015-41122D06-DF53-42C5-8139-FBECB05DC8E0Q37682676-609CA575-760B-4546-A935-F59602363FC4Q46087408-A8CA67FE-38EF-4914-B337-F5B4B9E8BEC5Q52429827-0BC41F5C-7A57-4DA6-93AE-A18CCCDDE1A8Q55284165-78B1BB8C-84BE-46B4-A5FB-355CD0945638
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Optimizing exon skipping therapies for DMD.
@ast
Optimizing exon skipping therapies for DMD.
@en
Optimizing exon skipping therapies for DMD.
@nl
type
label
Optimizing exon skipping therapies for DMD.
@ast
Optimizing exon skipping therapies for DMD.
@en
Optimizing exon skipping therapies for DMD.
@nl
prefLabel
Optimizing exon skipping therapies for DMD.
@ast
Optimizing exon skipping therapies for DMD.
@en
Optimizing exon skipping therapies for DMD.
@nl
P2093
P2860
P1433
P1476
Optimizing exon skipping therapies for DMD.
@en
P2093
P2860
P304
P577
2007-12-01T00:00:00Z